Roche reported 15.5% weight loss in enicepatide’s highest-dose group. A look at the Phase II diabetes findings and limits after 35.
On September 22, 2026, Roche announced positive topline results from CT-388-104, its Phase II trial of investigational enicepatide (CT-388). The study tested a once-weekly medicine in adults with type 2 diabetes and overweight or obesity.
Roche describes enicepatide as a dual GLP-1/GIP receptor agonist intended to affect appetite and blood-sugar regulation. The company said the trial met both primary endpoints: change in HbA1c and change in body weight at week 48. It described the effects as dose-dependent.
The main findings were:
The weight result and the HbA1c result answer different questions. The HbA1c change is expressed in percentage points, while the weight change is expressed as a percentage of starting body weight. Those figures should not be read as interchangeable measures of improvement.
For a reader focused on appearance, the weight figure may attract attention first. The blood-sugar finding deserves equal space in this story. That pairing makes the announcement relevant to a clinical conversation about metabolic care rather than simply a before-and-after comparison.
These are company-reported Phase II findings, not an approval for routine use. Roche’s release provides no numerical placebo results for weight loss or HbA1c. It also omits a full dose-by-dose efficacy table and statistical details such as confidence intervals and p-values. Those omissions prevent a complete assessment of the reported treatment effect relative to placebo.
The safety account is also limited. The announcement does not include a detailed adverse-event table or longer-term safety results. A low discontinuation rate is not the same thing as a complete description of unwanted effects.
Roche reported “no demonstrable plateau” in weight loss during the study. That statement applies to the reported 48-week observation period, not to an indefinite forecast of continued weight loss.
The population defines another boundary: the findings concern adults with both type 2 diabetes and overweight or obesity. The same outcome is not established for people without diabetes. The announcement also does not establish superiority over other treatments or protection from cardiovascular complications.
Finally, the reported endpoints were body weight and HbA1c. They do not establish muscle retention or improvements in sexual wellbeing or lifespan. Reaching the company’s stated glucose thresholds should not be rewritten as proof that participants were cured of diabetes.
For a man over 35 thinking about long-term health, this news belongs in a conversation about what he wants care to achieve. It need not become another deadline to change his body.
For a reader living with diabetes, the two reported endpoints invite a more specific conversation than “How much weight might I lose?” Ask a qualified clinician which outcomes matter in your own care and how a treatment decision would be assessed. That discussion can place laboratory results and body-weight goals alongside daily function.
Bring questions about your current care rather than treating the announcement as a request for a particular medicine. A useful consultation distinguishes interest in research from a decision about treatment. Personal eligibility and suitability remain questions for qualified care.
It helps to name your priorities plainly. Wanting better blood-sugar control is not identical to wanting a smaller waist. Wanting to feel stronger is another priority again. Keeping those aims distinct makes the conversation more precise without requiring you to dismiss any of them.
The useful adjustment here is to expectations rather than to your weekly schedule. Keep routine decisions anchored to evidence relevant to those decisions. A clinical trial’s reporting period does not need to become a personal transformation deadline.
For a man balancing work with training or a social life, the practical question is what deserves attention now. Strength, energy and confidence can sit alongside weight-related goals rather than being replaced by them. Keep a wider view of body-composition progress in the conversation instead of allowing one headline number to set every goal.
There is no need to turn interest in a developing medicine into an all-or-nothing position on health. You can follow the research while keeping your present care decisions with a qualified clinician. Curiosity does not require an immediate change in behavior.
A practical response is to prepare a short set of discussion points:
The purpose is to connect the news to your actual priorities. It is more useful to leave a consultation understanding the reasoning behind care than to leave with a trial percentage as a personal target.
Keep the discussion specific about everyday life too. Say whether your main concern is confidence, physical capability or the burden of managing your health. Those are different concerns and deserve room in the conversation rather than being compressed into a single weight goal.
It is reasonable to care about how your body looks. It is also reasonable to want health coverage that does not turn every metabolic result into a test of attractiveness.
For gay men over 35, an adult reading of this news leaves room for both interests. Weight can be a personal goal without becoming a condition for dating, intimacy or participation in community life. No particular physique needs to serve as the price of belonging.
The point is not to give up on appearance. It is to place appearance within a fuller set of priorities that includes comfort, relationships and how you want to live. A research headline can inform that picture without taking it over.
In its announcement, Roche said the Phase III chronic weight-management studies ENITH-1 and ENITH-2 were ongoing. It also said it planned to start a Phase III glycemic-control program and cardiovascular-outcomes trials in the first half of 2027. Those are development plans reported by the company.
For readers following the research, the next useful material will be more complete efficacy reporting and fuller safety results. Pay attention to the participant population and the outcome being measured before comparing a future result with this one. Reading about realistic expectations for weight-management medicines can help frame those questions without turning separate trials into a simple ranking.
Treat Roche’s enicepatide announcement as a reason to ask better questions about metabolic care, not as a reason to change treatment or make a trial average your personal body goal.
A trial’s average weight change is not a measure of personal appeal, a distinction GayFitLab brings to its editorial approach. For gay men 35+ seeking adult coverage of dating and community, the publication places health and appearance alongside confidence and relationships without turning gay life into a stereotype.
Stay connected for research-led guidance on fitness, body composition, skin, grooming, vitality, sexual wellbeing, relationships and healthy aging. Clear ideas for gay men 35+ who want to look good, feel strong and age with confidence.
Build habits and systems that support clear thinking, steady energy and long term capacity throughout a demanding career.
explore the Blog
